This is a different patent battle to Repatha v Praulent. Amgen...

This is a different patent battle to Repatha v Praulent. Amgen doesnt have a competing product v Duplimumab so the worst case scenario is Amgen will get $$ damages or royalties on Duplimumab.

I'm not entirely convinced Duplimumab is in a WI by the way. Logic seems to escape Sanofi at the best of times. You'd think they'd go with a WI that has connectivity which would go some way to convincing payers to cough up for the $30,000 cost. They didnt do that with Praulent. They'd rather make a few bucks saving (difference between the cost of an WI and AI) and stick with an AI, and lose out on thousands of dollars by not having connectivity and giving one more reason for payers to say no to the high cost of Praulent. Amgen doesnt have connectivity either with Smartdose.

Until I see photographic evidence of Duplimumab in an WI, I'm leaning towards Sanofi being the great procrastinator that it is....